Before starting the study, both the drug group and the placebo group had the same muscle energy recovery ability, so any later differences weren’t due to starting out differently.
Scientific Claim
In obese adults with reduced GH, the initial rate of phosphocreatine recovery (ViPCr) at baseline did not differ significantly between those who later received tesamorelin or placebo, indicating baseline mitochondrial function was comparable between groups.
Original Statement
“At baseline, there were no differences in age, sex, race/ethnicity, and GH or PCr parameters between tesamorelin and placebo.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
This is a direct comparison of baseline data from an RCT. The absence of significant differences is a factual statement supported by the data.
Evidence from Studies
Supporting (1)
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.
Before any treatment, both groups of obese adults — whether they got the real drug or a dummy pill — had the same level of muscle energy recovery, meaning their mitochondria were working just as well at the start.